TipRanks (Tue, 23-Dec 8:45 AM ET)
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
Globe Newswire (Mon, 24-Nov 7:00 AM ET)
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
Globe Newswire (Wed, 5-Nov 7:00 AM ET)
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
Globe Newswire (Tue, 4-Nov 8:00 AM ET)
Globe Newswire (Fri, 24-Oct 1:15 PM ET)
Globe Newswire (Tue, 21-Oct 7:00 AM ET)
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
Globe Newswire (Wed, 1-Oct 4:05 PM ET)
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Sionna Therapeutics trades on the NASDAQ stock market under the symbol SION.
As of December 23, 2025, SION stock price climbed to $43.44 with 180,122 million shares trading.
SION has a beta of 1.08, meaning it tends to be more sensitive to market movements. SION has a correlation of 0.04 to the broad based SPY ETF.
SION has a market cap of $1.94 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that SION belongs to (by Net Assets): VTI, XBI, IWM, IBB, VXF.
SION support price is $40.51 and resistance is $44.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SION shares will trade within this expected range on the day.